Richard Pazdur, FDA Cancer Chief, Discusses 25 Years of InnovationCancer treatment has evolved significantly over the past 25 years, enabling more targeted therapies and improved patient outcomes.
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedalsThe FDA's decision to change a prior ruling alleviated patient access issues but raised safety concerns regarding compounded drugs.
The Future of Psychedelic Research Is In Limbo - Why the FDA's Decision Changed EverythingThe FDA declined Lykos Therapeutics' MDMA-assisted therapy application, signaling challenges for psychedelic drug approval.
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedalsThe FDA's decision to change a prior ruling alleviated patient access issues but raised safety concerns regarding compounded drugs.
The Future of Psychedelic Research Is In Limbo - Why the FDA's Decision Changed EverythingThe FDA declined Lykos Therapeutics' MDMA-assisted therapy application, signaling challenges for psychedelic drug approval.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
Ex-NYC COVID czar details in secret recording how to use media to 'spin' monkeypox drug storiesDr. Jay Varma's comments suggest manipulative media tactics were utilized to gain FDA approval for a drug with questionable efficacy.
First drug to slow Alzheimer's too costly for NHSNICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs.
Biogen Abandons Its Controversial Alzheimer's Drug AduhelmBiogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks.
Lilly's Alzheimer's drug faces delayed reckoningFDA advisers are reviewing Eli Lilly's Alzheimer's drug application, impacting future treatments targeting amyloid plaques.
First drug to slow Alzheimer's too costly for NHSNICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs.
Biogen Abandons Its Controversial Alzheimer's Drug AduhelmBiogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks.
Lilly's Alzheimer's drug faces delayed reckoningFDA advisers are reviewing Eli Lilly's Alzheimer's drug application, impacting future treatments targeting amyloid plaques.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
Daily briefing: Millions of mosquitos deployed to save Hawaii's birdsMemories might be formed in the primary visual cortex, not just the eyes.
Daily briefing: 'I had no choice but to commit misconduct'Elephants use proper names to address each other, a behavior unique to humans.